Zacks Investment Research lowered shares of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) from a hold rating to a sell rating in a report issued on Friday.
According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “
Several other equities research analysts have also issued reports on the stock. BidaskClub lowered shares of Adamas Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday, July 19th. Noble Financial restated a buy rating on shares of Adamas Pharmaceuticals in a report on Friday, May 12th. Mizuho restated a buy rating and issued a $26.00 target price on shares of Adamas Pharmaceuticals in a report on Tuesday, June 6th. Finally, Cowen and Company restated an outperform rating and issued a $45.00 target price on shares of Adamas Pharmaceuticals in a report on Sunday, May 28th. Two analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. Adamas Pharmaceuticals presently has a consensus rating of Hold and an average target price of $29.00.
Shares of Adamas Pharmaceuticals (ADMS) opened at 15.28 on Friday. Adamas Pharmaceuticals has a 1-year low of $12.10 and a 1-year high of $19.50. The firm has a 50-day moving average of $17.19 and a 200 day moving average of $16.86. The company’s market capitalization is $344.01 million.
Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.81) by $0.12. Adamas Pharmaceuticals had a negative return on equity of 52.91% and a negative net margin of 10,499.65%. The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.03 million. During the same period in the previous year, the business earned ($0.78) earnings per share. The business’s quarterly revenue was down 90.9% on a year-over-year basis. On average, analysts anticipate that Adamas Pharmaceuticals will post ($3.71) EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Adamas Pharmaceuticals, Inc. (ADMS) Lowered to Sell at Zacks Investment Research” was originally reported by Community Financial News and is owned by of Community Financial News. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.com-unik.info/2017/08/15/adamas-pharmaceuticals-inc-adms-lowered-to-sell-at-zacks-investment-research.html.
In related news, major shareholder Great Point Partners Llc sold 350,000 shares of Adamas Pharmaceuticals stock in a transaction dated Monday, June 19th. The shares were sold at an average price of $17.05, for a total transaction of $5,967,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 731,041 shares of company stock valued at $12,476,149 in the last quarter. 29.00% of the stock is currently owned by company insiders.
Several large investors have recently bought and sold shares of the stock. Emerald Advisers Inc. PA raised its stake in Adamas Pharmaceuticals by 2.7% in the second quarter. Emerald Advisers Inc. PA now owns 532,727 shares of the specialty pharmaceutical company’s stock valued at $9,317,000 after buying an additional 14,042 shares in the last quarter. Parametric Portfolio Associates LLC raised its stake in Adamas Pharmaceuticals by 153.3% in the first quarter. Parametric Portfolio Associates LLC now owns 111,788 shares of the specialty pharmaceutical company’s stock valued at $1,956,000 after buying an additional 67,654 shares in the last quarter. State Street Corp raised its stake in Adamas Pharmaceuticals by 6.3% in the fourth quarter. State Street Corp now owns 257,685 shares of the specialty pharmaceutical company’s stock valued at $4,356,000 after buying an additional 15,216 shares in the last quarter. Wells Fargo & Company MN raised its stake in Adamas Pharmaceuticals by 28.4% in the first quarter. Wells Fargo & Company MN now owns 15,166 shares of the specialty pharmaceutical company’s stock valued at $266,000 after buying an additional 3,358 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in Adamas Pharmaceuticals by 212.9% in the first quarter. Goldman Sachs Group Inc. now owns 60,897 shares of the specialty pharmaceutical company’s stock valued at $1,066,000 after buying an additional 41,436 shares in the last quarter. Institutional investors and hedge funds own 70.86% of the company’s stock.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Adamas Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Adamas Pharmaceuticals Inc. and related companies.